Meeting
2015 ASCO Annual Meeting
Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC).
Authors
Rosa Nadal
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Rosa Nadal , Asim Amin , Daniel M. Geynisman , Martin Henner Voss , Matthew Weinstock , Jaime Doyle , Zhe Zhang , Antonio Viudez , Elizabeth R. Plimack , David F. McDermott , Robert Motzer , Brian I. Rini , Hans J. Hammers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4566)
DOI
10.1200/jco.2015.33.15_suppl.4566
Abstract #
4566
Poster Bd #
240
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Second-line prescribing preferences (PPrefs) of U.S.-based medical oncologists’ (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Charles J. Ryan
Poster
2023 ASCO Annual Meeting
Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.
First Author: Arthur Geraud
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2022 ASCO Genitourinary Cancers Symposium
Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma.
First Author: Xieqiao Yan